Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - feline panleukopenia virus (cu4 virus strain) inactivated, feline calcivirus (255 virus strain) inactivated, feline rhinotracheitis virus (605 virus strain) inactivated, chlamydophila felis (inactivated) (cello strain) - suspension for injection - unknown - inactivated feline panleucopenia virus / parvovirus vaccine + inactivated feline rhinotracheitis vi - feline - immunological - inactivated vaccine

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - inactivated feline panleukopenia virus (fpv) , feline calicivirus (fcv) , feline herpesvirus (fhv) vaccine (vet.) - emulsion for injection (sc) - formulation: each dose (1 ml) contains: inactivated feline panleukopenia (fp) virus (fpv-bio 7 strain) .......... <10^3 tcid50 feline calicivirus (fcv) (fcv-bio 8 strain) ...............< 10^5.5 tcido feline herpesvirus (fhv) (fhv-1-bio 9)........<10% tcid50 tcid - median tissue culture infectious dose

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - inactivated feline panleukopenia virus (fpv) , feline calicivirus (fcv) , feline herpesvirus (fhv) , rabies virus (rv) vaccine (vet.) - emulsion for injection (sc) - : formulation: each ml (dose) contains: inactivated feline panleukopenia virus (fpv) (fpv-bio 7 strain) ....... > 10^3 tcid50 feline calicivirus (fcv) (fcv-bio 8 strain) ............. > 10^5.5 tcid 50 feline herpesvirus (fhv) (fhv-1-bio 8).............. > 10^5 tcid 50 rabies virus (msv bio 16-vnukovo-32 strain)........... >.1 iu tcid - tissue culture infectious dose iu - international unit

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), panleucopenia virus (pli iv) and inactivated calicivirus (fcv 431) and (fcv g1 strains) - suspension for injection (sc) - 1 dose of 1 ml or 0.5 ml contains attenuated feline rhinotracheitis herpesvirus(fhv f2 strain)≥104.9 ccid50; inactivated feline calicivirus (fcv 431 and fcv g1 strains) antigens≥ 2.0 elisa u.; attenuated feline panleucopenia virus (pli iv) ≥103.5 ccid50

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fort dodge australia pty limited - feline calicivirus | feline rhinotracheitis - immunotherapy - cat | kitten | cat - queen | cat - tom | kitten | young cat - feline calicivirus | feline rhinotracheitis | vaccine | calicivirus (feline) | equine rotavirus | fcv | feline herpesvirus type 1 | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | rhinotracheitis (feline)

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs.onsets of immunity isone week after primary vaccination course.the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs.onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and chlamydophila felis components.the duration of immunity is 1 year after the last (re-)vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs.onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.